RESUMEN
Induced pluripotent stem (iPS) cells are human somatic cells that have been reprogrammed to a pluripotent state. There are several hurdles to be overcome before iPS cells can be considered as a potential patient-specific cell therapy, and it will be crucial to characterize the developmental potential of human iPS cell lines. As a research tool, iPS-cell technology provides opportunities to study normal development and to understand reprogramming. iPS cells can have an immediate impact as models for human diseases, including cancer
Asunto(s)
Investigación Biomédica , Tratamiento Basado en Trasplante de Células y Tejidos , Células Madre Pluripotentes/citología , HumanosRESUMEN
The International Society for Stem Cell Research (ISSCR) task force that developed new Guidelines for the Clinical Translation of Stem Cells discusses core principles that should guide the responsible transition of basic stem cell research into appropriate clinical applications.
Asunto(s)
Tecnología Biomédica/normas , Tratamiento Basado en Trasplante de Células y Tejidos/normas , Ensayos Clínicos como Asunto/normas , Guías de Práctica Clínica como Asunto/normas , Trasplante de Células Madre/normas , Animales , Tecnología Biomédica/ética , Tratamiento Basado en Trasplante de Células y Tejidos/ética , Comités de Monitoreo de Datos de Ensayos Clínicos/normas , Ensayos Clínicos como Asunto/ética , Humanos , Consentimiento Informado/normas , Monitoreo Fisiológico/normas , Revisión por Pares/normas , Trasplante de Células Madre/éticaRESUMEN
The Juvenile Diabetes Research Foundation International (JDRF) was founded in 1970 by parents of children with juvenile diabetes to find a cure for diabetes and its complications through the support of research. The foundation was an early supporter of stem cell research, recognizing the promise of stem cells to quicken the pace of discovery for a cure for juvenile diabetes. The JDRF has committed considerable resources to supporting stem cell research in both the United States and abroad. In the United States, the organization has been an advocate on the state and national level for increased funding and for expansion of current federal policy restricting embryonic stem (ES) cell research.